4basebio PLC (FRA:88Q)
Germany flag Germany · Delayed Price · Currency is EUR
13.00
0.00 (0.00%)
Last updated: Jun 5, 2025

4basebio Statistics

Total Valuation

4basebio has a market cap or net worth of EUR 204.05 million. The enterprise value is 180.75 million.

Market Cap 204.05M
Enterprise Value 180.75M

Important Dates

The last earnings date was Friday, May 9, 2025.

Earnings Date May 9, 2025
Ex-Dividend Date n/a

Share Statistics

Current Share Class 15.48M
Shares Outstanding n/a
Shares Change (YoY) +6.47%
Shares Change (QoQ) +6.41%
Owned by Insiders (%) n/a
Owned by Institutions (%) n/a
Float 3.44M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 180.86
PB Ratio 6.40
P/TBV Ratio 6.67
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings -12.12
EV / Sales 163.11
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF -13.07

Financial Position

The company has a current ratio of 11.30, with a Debt / Equity ratio of 0.58.

Current Ratio 11.30
Quick Ratio 11.08
Debt / Equity 0.58
Debt / EBITDA n/a
Debt / FCF -1.33
Interest Coverage -17.01

Financial Efficiency

Return on equity (ROE) is -95.28% and return on invested capital (ROIC) is -31.01%.

Return on Equity (ROE) -95.28%
Return on Assets (ROA) -28.23%
Return on Invested Capital (ROIC) -31.01%
Return on Capital Employed (ROCE) -30.85%
Revenue Per Employee 11,170
Profits Per Employee -147,658
Employee Count 84
Asset Turnover 0.03
Inventory Turnover 0.86

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -21.21% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change -21.21%
50-Day Moving Average 13.14
200-Day Moving Average 14.57
Relative Strength Index (RSI) 50.45
Average Volume (20 Days) 186

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, 4basebio had revenue of EUR 1.13 million and -14.91 million in losses. Loss per share was -1.14.

Revenue 1.13M
Gross Profit 761,818
Operating Income -15.47M
Pretax Income -15.30M
Net Income -14.91M
EBITDA -14.56M
EBIT -15.47M
Loss Per Share -1.14
Full Income Statement

Balance Sheet

The company has 42.12 million in cash and 18.40 million in debt, giving a net cash position of 23.72 million.

Cash & Cash Equivalents 42.12M
Total Debt 18.40M
Net Cash 23.72M
Net Cash Per Share n/a
Equity (Book Value) 31.90M
Book Value Per Share 2.06
Working Capital 40.66M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -12.99 million and capital expenditures -842,836, giving a free cash flow of -13.83 million.

Operating Cash Flow -12.99M
Capital Expenditures -842,836
Free Cash Flow -13.83M
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross Margin 67.52%
Operating Margin -1,371.17%
Pretax Margin -1,356.27%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

4basebio does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -6.47%
Shareholder Yield n/a
Earnings Yield -7.31%
FCF Yield -6.78%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

4basebio has an Altman Z-Score of 3.79.

Altman Z-Score 3.79
Piotroski F-Score n/a